Future options in the treatment of ErbB2 (HER2)-positive breast cancer

European Journal of Cancer, Supplement

Volumn 6, Issue 5, 2008, Pages 25-31

  Fumoleau, Pierre ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Breast neoplasms; HER2; Lapatinib; Receptor, epidermal growth factor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLACEBO; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ABDOMINAL CRAMP; ADJUVANT THERAPY; ANOREXIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPIGMENTATION; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG TARGETING; FATIGUE; HAIR DISEASE; HUMAN; INDIVIDUALIZATION; METASTASIS; METASTASIS INHIBITION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 41149103928     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(08)70277-5     Document Type: Article

References (32)

1. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 19 (2005) 4265-4274
2. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
3. Smith I. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs 12 Suppl 4 (2001) S3-S10
4. Burstein H., Kuter I., Campos S., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19 10 (2001) 2722-2730
5. Konecny G., Pegram M., Venkatesan N., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 3 (2006) 1630-1639
6. Spector N., Xia W., Burris III H., et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23 11 (2005) 2502-2512
7. Hegde P., Rusnak D., Bertiaux M., et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 6 5 (2007) 1629-1640
8. Mahmoud-Ahmed A., Suh J., Lee S., Crownover R., and Barnett G. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 54 3 (2002) 810-817
9. Tsao M., Sultanem K., Chiu D., et al. Supportive care management of brain metastases: what is known and what we need to know. Conference proceedings of the National Cancer Institute of Canada (NCIC) Workshop on Symptom Control in Radiation Oncology. Clin Oncol (R Coll Radiol) 15 7 (2003) 429-434
10. Palmieri D., Smith Q., Lockman P., et al. Brain metastases of breast cancer. Breast Dis 26 (2006) 139-147
11. Tham Y., Sexton K., Kramer R., Hilsenbeck S., and Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107 4 (2006) 696-704
12. Tosoni A., Ermani M., and Brandes A. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev Oncol Hematol 52 3 (2004) 199-215
13. Patyna S., Laird A., Mendel D., et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 5 7 (2006) 1774-1782
14. Agus D., Akita R., Fox W., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 2 (2002) 127-137
15. Baselga J., Cameron D., Miles D., et al. Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol ASCO Annual Meeting Proceedings 25 18S (2007) Abstract #1004.
16. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008 Jan 11; Epub ahead of print.
17. Yen L., You X., Al Moustafa A., et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19 31 (2000) 3460-3469
18. Konecny G., Meng Y., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10 5 (2004) 1706-1716
19. Yang J., Haworth L., Sherry R., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
20. Pegram M., Chan D., Dichmann R., et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 100 Suppl 1 (2006) Abstract #301.
21. Dejonge M., Savage S., Verweij J., et al. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J Clin Oncol ASCO Annual Meeting Proceedings 24 18 Suppl (2006) Abstract #3088.
22. Alltaha R, Cromwell E, Ducatman B, Higa G, Abraham J. Risk of brain metastases in HER2/neu-positive breast cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proc 2004;22(14S): Abstract #682.
23. Bendell J., Domchek S., Burstein H., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 12 (2003) 2972-2977
24. Clayton A., Danson S., Jolly S., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91 4 (2004) 639-643
25. Stemmler H., Kahlert S., Siekiera W., Untch M., Heinrich B., and Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15 2 (2006) 219-225
26. Yau T., Swanton C., Chua S., et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45 2 (2006) 196-201
27. Pelletier E., Shim B., Goodman S., and Amonkar M. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat 108 2 (2008) 297-305
28. Lin N., Dieras V., Paul D., et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol ASCO Annual Meeting Proceedings 25 18S (2007). http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview =abst_detail_view&confID=47&abstractID=35084 Abstract #1012. Presentation available at: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vm view=abst_detail_view&confID=47&abstractID=35084.
29. Lin N., Carey L., Liu M., et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol ASCO Annual Meeting Proceedings 24 18S (2006) Abstract #503.
30. Moy B, Maltzman JD, Goss PE. Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with ErbB2-overexpressing breast cancer: Tykerb evaluation after chemotherapy
31. Piccart-Gebhart M., Perez E., Baselga J., et al. ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 206/N063D/EGF106708]: a phase III study for HER2-overexpressing early breast cancer (BC). Breast 16 Suppl 1 (2007) S46 (Abstract P118).
32. Baselga J., Piccart-Gebhart M., Gelber R., et al. neo-ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 106/SOLTI/EGF106903]: a phase III translational study for Her2-overexpressing early breast cancer (BC). Breast 16 Suppl 1 (2007) S48 (Abstract P124).